Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0IK5R
|
|||
| Drug Name |
ERY974
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | Phase 1 | [1] | |
| Company |
Chugai Pharma USA Berkeley Heights, NJ
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Glypican-3 (GPC3) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Proteoglycans in cancer | |||
| NetPath Pathway | IL2 Signaling Pathway | |||
| Pathway Interaction Database | Glypican pathway | |||
| Glypican 3 network | ||||
| Reactome | A tetrasaccharide linker sequence is required for GAG synthesis | |||
| HS-GAG degradation | ||||
| Retinoid metabolism and transport | ||||
| WikiPathways | Visual phototransduction | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.